Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1251 to 1300 of 1372 results for patients and public

  1. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  2. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    Awaiting development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    Awaiting development

  3. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  4. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  6. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221

    In development [GID-TA11183] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. MRI guided focused ultrasound subthalamotomy in parkinson's disease

    Awaiting development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  12. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease

    Awaiting development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  14. Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

    In development [GID-TA11039] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  15. Zuranolone for treating severe postnatal depression ID6431

    Awaiting development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  18. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  19. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]

    In development [GID-TA11495] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Targeted Muscle Reinnervation for refractory pain after limb amputation

    Awaiting development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    Awaiting development

  22. Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: TBC

    Health technology evaluations
    In development

  24. Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]

    Awaiting development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: TBC

    Health technology evaluations
    In development

  26. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: TBC

    Health technology evaluations
    In development

  27. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  28. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Artificial intelligence software to help detect fractures in the emergency department (provisional title)

    In development [GID-HTE10044] Expected publication date: 17 December 2024

    Health technology evaluations
    In development

  33. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction

    Awaiting development [GID-IPG10353] Expected publication date: 14 November 2024

    Interventional procedures guidance
    Awaiting development

  36. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]

    In development [GID-TA11450] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  38. Tenecteplase for treating acute ischaemic stroke [ID6306]

    In development [GID-TA11364] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Linzagolix for treating pain caused by endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  41. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development

  43. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury

    Awaiting development [GID-IPG10367] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  47. Phrenic nerve pacing for congenital central hypoventilation syndrome

    Awaiting development [GID-IPG10317] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  48. Caval valve implantation for tricuspid regurgitation

    Awaiting development [GID-IPG10344] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  49. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development